API Positions and Papers
The Association for Pathology Informatics is a largely volunteer-based organization consisting of professionals engaged in pathology informatics. In addition to conducting important research, carrying out essential clinical practices, and leading crucial initiatives, many of our members are involved in assessing matters that have direct bearing on the adaptation and implementation of technologies and workflows seeking to improve health standards and care for the patient community. Often times, the positions that are taken reflect the standards and goals of API and are thus reflected in joint letters or papers on behalf of the Society and its members. Below, you can find its most recent positions on salient issues:
- Letter in support of the CRA resolution disapproving of the FDA laboratory developed test (LDT) final rule. June 7, 2024 Learn More
- In November 2023 API signed a joint statement to the FDA in support of proposed draft legislative proposal on CLIA modernization.
-
In October 2023 API signed a joint letter with 89 other organizations to the FDA to request an extension to the comment deadline to the Rulemaking Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests - October 31, 2023 Learn more
- Article in press: Recommendations for the Use of In silico Approaches for Next Generation Sequencing Bioinformatic Pipeline Validation: a Joint Report from Association for Molecular Pathology, College of American Pathologists, and The Association for Pathology Informatics - October 18, 2022 Learn More
- API’s response to CMS-2022-0119-0001 - August 24, 2022 Learn More
- API Letter to HHS about COVID-19 and remote sign out - March 24, 2020 Learn More
|
